Chemotherapy remains the mainstay of treatment in the majority of solid and haematological
malignancies. Resistance to cytotoxic chemotherapy is a major clinical problem and …

Since the discovery of MSP (macrophage-stimulating protein; also known as MST1 and
hepatocyte growth factor-like (HGFL)) as the ligand for the receptor tyrosine kinase RON …

Successfully developed target-based therapies have significantly changed cancer treatment.
Among many targets, the c-MET receptor tyrosine kinase and its ligand hepatocyte growth …

For each cancer type, only a few genes are informative. Due to the so-called 'curse of
dimensionality'problem, the gene selection task remains a challenge. To overcome this …

The MET/hepatocyte growth-factor (HGF) signaling pathway plays a key role in the
processes of embryogenesis, wound healing, and organ regeneration. Aberrant activation of …

In microarray experiments, the sample size is considerably smaller than that of the feature
size, thereby imposing the curse of dimensionality problem. To resolve this issue …

Colorectal cancer (CRC) is the third most common cancer and a common cause of cancer‐
related mortality globally. In spite of the improvements in the early diagnosis of CRC …

Background The KRAS mutation is not responsible for all cases of resistance to anti–
epidermal growth factor receptors (EGFRs) in metastatic colorectal cancer (mCRC), and new …

Recepteur d'origine nantais (RON, MST1R) is a single-span transmembrane receptor
tyrosine kinase (RTK) aberrantly expressed in numerous cancers, including various solid …

c-Met (mesenchymal–epithelial transition factor) is a tyrosine kinase receptor activated by
hepatocyte growth factor and regulates multiple biological processes, such as cell …